<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604539</url>
  </required_header>
  <id_info>
    <org_study_id>CS/IV-SIN-01</org_study_id>
    <secondary_id>CS/IV-SIN-01</secondary_id>
    <nct_id>NCT00604539</nct_id>
  </id_info>
  <brief_title>Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioiberica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a chondroitin sulphate conventional
      treatment on the degree of severity of synovitis, as measured by magnetic resonance in
      patients with knee OA with clinical synovitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the change in the severity of synovitis measured by MRI according to the modified methods of Loeuille et al. after chondroitin sulphate treatment in patients with knee OA and clinical signs of synovitis</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of cartilage volume and subchondral bone lesions</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain measured by VAS</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC index</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Questionaire</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of joint swelling, effusion</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Synovitis</condition>
  <condition>Osteoarthritis</condition>
  <condition>Joint Diseases</condition>
  <condition>Muskuloskeletal Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chondroitin sulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulphate (Condrosan)</intervention_name>
    <description>800 mg (two capsules of 400 mg each) taken once a day for one year</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary OA of the knee according to ACR with synovitis criteria (warmth, swelling or
             effusion);

          -  OA of radiological stages 2 and 3 according to Kellgren-Lawrence;

          -  Minimum joint space width ≥2 mm in the medial femorotibial compartment on standing
             knee X-ray;

          -  VAS of pain while walking ≥40 mm.

        Exclusion Criteria:

          -  Known allergy to chondroitin sulphate;

          -  Progressive or serious pathologies (cancer, AIDS,...);

          -  Other bone and articular diseases (antecedents and/or current signs) such as
             chondrocalcinosis, Paget's disease, rheumatoid arthritis, aseptic osteonecrosis, gout,
             septic arthritis, ochronosis, acromegaly, hemochromatosis, Wilson's disease,
             osteochondromatosis;

          -  Corticosteroids (oral, injectable), indomethacin, therapeutic dose of glucosamine or
             chondroitin sulphate during the 12 weeks preceding inclusion;

          -  Hyaluronic Acid (intra-articular pathway) during the 26 weeks preceding inclusion;

          -  Radioactive synovectomy during the 12 weeks preceding inclusion;

          -  If the patient is receiving NSAID at baseline (D0), it should be maintained at a
             stable dosage as much as possible from D0 to D180. In the open phase of the study
             (D180 to D360), NSAID will also be allowed as rescue medication along with
             acetaminophen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Pelletier, Prof., Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ArthroLab Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanne Martel-Pelletier, Prof., Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ArthroLab Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inst. De Rhumatologie</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de recherche en rhumatologie et maladies osseuses</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de rhumatologie St-Louis</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche musculo-squelettique</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8A 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg M, Meyer JM, Cline GA, Pelletier JP. Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005 Apr;64(4):556-63. Epub 2004 Sep 16.</citation>
    <PMID>15374855</PMID>
  </reference>
  <reference>
    <citation>Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis : current status. Drugs Aging. 2005;22(2):141-61. Review.</citation>
    <PMID>15733021</PMID>
  </reference>
  <reference>
    <citation>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.</citation>
    <PMID>16495392</PMID>
  </reference>
  <reference>
    <citation>Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995 Nov;38(11):1541-6.</citation>
    <PMID>7488273</PMID>
  </reference>
  <reference>
    <citation>Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000 Jan;27(1):205-11.</citation>
    <PMID>10648040</PMID>
  </reference>
  <reference>
    <citation>Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, Netter P, Gillet P. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 2005 Nov;52(11):3492-501.</citation>
    <PMID>16255041</PMID>
  </reference>
  <reference>
    <citation>McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000 Mar 15;283(11):1469-75. Review.</citation>
    <PMID>10732937</PMID>
  </reference>
  <reference>
    <citation>Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86.</citation>
    <PMID>15751094</PMID>
  </reference>
  <reference>
    <citation>Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996 Aug;23(8):1385-91.</citation>
    <PMID>8856618</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M; EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005 May;64(5):669-81. Epub 2004 Oct 7. Review.</citation>
    <PMID>15471891</PMID>
  </reference>
  <reference>
    <citation>Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, Tannenbaum H, Meyer JM, Beary JF, Cline GA, Pelletier JP. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8(1):R21. Epub 2005 Dec 30.</citation>
    <PMID>16507119</PMID>
  </reference>
  <reference>
    <citation>Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003 Jul 14;163(13):1514-22.</citation>
    <PMID>12860572</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76. Erratum in: Osteoarthritis Cartilage. 2007 Aug;15(8):979. DeVathaire, Florent [corrected to de Vathaire, Florent].</citation>
    <PMID>15023378</PMID>
  </reference>
  <results_reference>
    <citation>Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011 Jun;70(6):982-9. doi: 10.1136/ard.2010.140848. Epub 2011 Mar 1.</citation>
    <PMID>21367761</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>December 16, 2011</last_update_submitted>
  <last_update_submitted_qc>December 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Josep Vergés, Scientific Medical Director</name_title>
    <organization>Bioibérica S.A.</organization>
  </responsible_party>
  <keyword>Chondroitin sulphate</keyword>
  <keyword>Synovitis</keyword>
  <keyword>Knee osteoarthritis</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Synovitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

